Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer: study protocol of the INDIBLADE trial

C. F. Stockem, J. J.J. Mellema, B. W.G. van Rhijn, T. N. Boellaard, M. L. van Montfoort, S. Balduzzi, J. L. Boormans, M. Franckena, R. P. Meijer, D. G.J. Robbrecht, B. B.M. Suelmann, E. E. Schaake, M. S. van der Heijden*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)
23 Downloads (Pure)

Abstract

Introduction: 

Studies that assessed the efficacy of pre-operative immune checkpoint blockade (ICB) in locally advanced urothelial cancer of the bladder showed encouraging pathological complete response rates, suggesting that a bladder-sparing approach may be a viable option in a subset of patients. Chemoradiation is an alternative for radical cystectomy with similar oncological outcomes, but is still mainly used in selected patients with organ-confined tumors or patients ineligible to undergo radical cystectomy. We propose to sequentially administer ICB and chemoradiation to patients with (locally advanced) muscle-invasive bladder cancer. 

Methods: 

The INDIBLADE trial is an investigator-initiated, single-arm, multicenter phase 2 trial. Fifty patients with cT2-4aN0-2M0 urothelial bladder cancer will be treated with ipilimumab 3 mg/kg on day 1, ipilimumab 3 mg/kg plus nivolumab 1 mg/kg on day 22, and nivolumab 3 mg/kg on day 43 followed by chemoradiation. The primary endpoint is the bladder-intact event-free survival (BI-EFS). Events include: local or distant recurrence, salvage cystectomy, death and switch to platinum-based chemotherapy. We will also evaluate the potential of multiparametric magnetic resonance imaging of the bladder to identify non-responders, and we will assess the clearance of circulating tumor DNA as a biomarker for ICB treatment response. 

Discussion: 

This is the first trial in which the efficacy of induction combination ICB followed by chemoradiation is being evaluated to provide bladder-preservation in patients with (locally advanced) urothelial bladder cancer. 

Clinical Trial Registration: 

The INDIBLADE trial was registered on clinicaltrials.gov on January 21, 2022 (NCT05200988).

Original languageEnglish
Article number1246603
JournalFrontiers in Oncology
Volume13
DOIs
Publication statusPublished - 29 Aug 2023

Bibliographical note

Funding Information:
The INDIBLADE trial is funded by Bristol Myers Squibb and the Dutch Cancer Society (KWF grant 13226). Acknowledgments

Publisher Copyright:
Copyright © 2023 Stockem, Mellema, van Rhijn, Boellaard, van Montfoort, Balduzzi, Boormans, Franckena, Meijer, Robbrecht, Suelmann, Schaake and van der Heijden.

Fingerprint

Dive into the research topics of 'Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer: study protocol of the INDIBLADE trial'. Together they form a unique fingerprint.

Cite this